title: Up-regulated microRNA-143 in cancer stem cells differentiation promotes prostate cancer cells metastasis by modulating FNDC3B expression.
abstract: BACKGROUND
  Metastatic prostate cancer is a leading cause of cancer-related death in men. Cancer stem cells (CSCs) are involved in tumor progression and metastasis, including in prostate cancer. There is an obvious and urgent need for effective cancer stem cells specific therapies in metastatic prostate cancer. MicroRNAs (miRNAs) are an important class of pervasive genes that are involved in a variety of biological functions, especially in cancer. The goal of this study was to identify miRNAs involved in prostate cancer metastasis and cancer stem cells.
  
  
  METHODS
  A microarray and qRT-PCR were performed to investigate the miRNA expression profiles in PC-3 sphere cells and adherent cells. A transwell assay was used to evaluate the migration of PC-3 sphere cells and adherent cells. MiR-143 was silenced with antisense oligonucleotides in PC-3, PC-3-M and LNCaP cells. The role of miR-143 in prostate cancer metastasis was measured by wound-healing and transwell assays in vitro and bioluminescence imaging in vivo. Bioinformatics and luciferase report assays were used to identify the target of miR-143.
  
  
  RESULTS
  The expression of miR-143 and the migration capability were reduced in PC-3 sphere cells and progressively increased during sphere re-adherent culture. Moreover, the down-regulation of miR-143 suppressed prostate cancer cells migration and invasion in vitro and systemically inhibited metastasis in vivo. Fibronectin type III domain containing 3B (FNDC3B), which regulates cell motility, was identified as a target of miR-143. The inhibition of miR-143 increased the expression of FNDC3B protein but not FNDC3B mRNA in vitro and vivo.
  
  
  CONCLUSIONS
  These data demonstrate for the first time that miR-143 was up-regulated during the differentiation of prostate cancer stem cells and promoted prostate cancer metastasis by repressing FNDC3B expression. This sheds a new insight into the post-transcriptional regulation of cancer stem cells differentiation by miRNAs, a potential approach for the treatment of prostate cancer.
authors: Center of medical research, Sun Yat-Sen memorial hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
authors: Xinlan
authors: X
authors: Fan
authors: Xu
authors: X
authors: Chen
authors: Weixi
authors: W
authors: Deng
authors: Guangzheng
authors: G
authors: Zhong
authors: Qingqing
authors: Q
authors: Cai
authors: Tianxin
authors: T
authors: Lin
mesh_terms: D002454:Cell Differentiation / Q000502:physiology; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000502:physiology; D005353:Fibronectins / Q000378:metabolism*; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000502:physiology*; D046228:Microarray Analysis; D009363:Neoplasm Proteins / Q000378:metabolism*; D014411:Neoplastic Stem Cells / Q000502:physiology*; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology; D012334:RNA, Neoplasm / Q000502:physiology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015854:Up-Regulation; D014945:Wound Healing / Q000502:physiology
chemical_list: C543006:FNDC3B protein, human; D005353:Fibronectins; C542359:MIRN143 microRNA, human; D035683:MicroRNAs; D009363:Neoplasm Proteins; D012334:RNA, Neoplasm
references: Nat Med. 2011 Feb;17(2):211-5
references: 21240262
references: Cell. 2007 Dec 14;131(6):1109-23
references: 18083101
references: Hepatology. 2009 Aug;50(2):490-9
references: 19472311
references: Eur Urol. 2011 May;59(5):671-81
references: 21296484
references: J Urol. 2009 Mar;181(3):1372-80
references: 19157460
references: Urol Oncol. 2012 May-Jun;30(3):314-8
references: 20843707
references: Cancer Res. 2005 Dec 1;65(23):10946-51
references: 16322242
references: Int J Cancer. 2010 Jul 15;127(2):394-403
references: 19585579
references: Carcinogenesis. 2013 Mar;34(3):530-8
references: 23188675
references: JAMA. 2007 May 2;297(17):1901-8
references: 17473300
references: Nat Rev Cancer. 2006 Nov;6(11):857-66
references: 17060945
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Int J Colorectal Dis. 2011 Oct;26(10):1279-85
references: 21670985
references: Mol Cell Biochem. 2011 Apr;350(1-2):207-13
references: 21197560
references: PLoS One. 2012;7(2):e31467
references: 22328933
references: BMC Cancer. 2012 Jan 20;12:29
references: 22260523
references: Nat Genet. 2002 Apr;30(4):363-4
references: 11896390
references: Biochim Biophys Acta. 2011 May;1813(5):683-94
references: 21277911
references: Nat Rev Cancer. 2008 Oct;8(10):755-68
references: 18784658
references: Oncol Rep. 2006 Dec;16(6):1403-10
references: 17089068
references: Biochem Biophys Res Commun. 2009 Jun 5;383(3):280-5
references: 19302977
references: Oncogene. 2007 Jun 28;26(30):4442-52
references: 17237814
references: Methods Mol Biol. 2009;568:139-49
references: 19582424
references: Mol Cancer Ther. 2012 May;11(5):1166-73
references: 22402125
references: Oncogene. 2006 Mar 16;25(12):1696-708
references: 16449977
references: BMC Cancer. 2012 Apr 10;12:143
references: 22490015
references: Nat Rev Cancer. 2001 Oct;1(1):34-45
references: 11900250